Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06317285 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT06317285 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 158 participants.
The verdict
NCT06317285, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Interventions
- DRUG Placebo
- DRUG GSK3915393
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2024-04-04 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06317285
The ClinicalTrials.gov registry entry for NCT06317285 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06317285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06317285 about?
NCT06317285 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)". Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participant...
What is the current status of trial NCT06317285?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2024-04-04. Estimated completion is 2025-10-01.
What interventions are being tested in trial NCT06317285?
The interventions under investigation include: Placebo (DRUG), GSK3915393 (DRUG).
Who is sponsoring clinical trial NCT06317285?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.